Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma.
暂无分享,去创建一个
S. Barrans | G. Morgan | I. Carter | F. Davies | A. Jack | A. Haynes | R. Owen | Gareth J Morgan | Faith E Davies | Roger G Owen | Andrew S Jack | R. Patmore | Sharon L Barrans | Ian Carter | Russell D Patmore | Andrew P Haynes
[1] R. Kanamaru,et al. Influence of p53 mutation on pathological grade, but not prognosis of non-Hodgkin's lymphoma. , 1999, Anti-cancer drug design.
[2] H. Asaoku,et al. Expressions of p53 and PCNA do not correlate with the international index or early response to chemotherapy in non‐Hodgkin's Lymphoma , 1998, American journal of hematology.
[3] G. Gaidano,et al. Molecular heterogeneity of B‐lineage diffuse large cell lymphoma , 1996, Genes, chromosomes & cancer.
[4] P. Guldberg,et al. Concurrent disruption of p16INK4a and the ARF-p53 pathway predicts poor prognosis in aggressive non-Hodgkin's lymphoma , 2000, Leukemia.
[5] S. Davis,et al. p53 gene mutations in multiple myeloma. , 1997, Molecular pathology : MP.
[6] D. Louis,et al. Aberrations of the p53 pathway components p53, MDM2 and CDKN2A appear independent in diffuse large B cell lymphoma , 1999, Leukemia.
[7] I. Maclennan,et al. Germinal center cells express bcl‐2 protein after activation by signals which prevent their entry into apoptosis , 1991, European journal of immunology.
[8] C. Finlay,et al. The mdm-2 oncogene can overcome wild-type p53 suppression of transformed cell growth , 1993, Molecular and cellular biology.
[9] S. Pittaluga,et al. BCL‐6 EXPRESSION IN REACTIVE LYMPHOID TISSUE AND IN B‐CELL NON‐HODGKIN'S LYMPHOMAS , 1996, The Journal of pathology.
[10] K. Franssila,et al. BCL2 overexpression associated with chromosomal amplification in diffuse large B-cell lymphoma. , 1997, Blood.
[11] H. Saito,et al. Overexpression of the MDM2 oncogene in leukemia and lymphoma. , 1996, Leukemia & lymphoma.
[12] M. Oren,et al. mdm2 expression is induced by wild type p53 activity. , 1993, The EMBO journal.
[13] J Hermans,et al. Clinical significance of bcl2 and p53 protein expression in diffuse large B-cell lymphoma: a population-based study. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] K. Yoshimoto,et al. Multiple fluorescence-based PCR-SSCP analysis. , 1994, BioTechniques.
[15] R Tibshirani,et al. Expression of a single gene, BCL-6, strongly predicts survival in patients with diffuse large B-cell lymphoma. , 2001, Blood.
[16] J. Beesley. Immunocytochemistry : a practical approach , 1993 .
[17] T. Jacks,et al. DNA damage can induce apoptosis in proliferating lymphoid cells via p53-independent mechanisms inhibitable by Bcl-2 , 1994, Cell.
[18] J Diebold,et al. Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Groupe d'Etude des Lymphomes de l'Adulte (GELA). , 1996, Blood.
[19] Biochemical and genetic control of apoptosis: relevance to normal hematopoiesis and hematological malignancies. , 1999 .
[20] M. Piris,et al. The expression of p53 protein in non-Hodgkin's lymphomas is not always dependent on p53 gene mutations. , 1993, Blood.
[21] Ash A. Alizadeh,et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.
[22] M. Piris,et al. Clinical outcome in diffuse large B-cell lymphoma is dependent on the relationship between different cell-cycle regulator proteins. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] A. Børresen-Dale,et al. Oncogenic aberrations in the p53 pathway are associated with a high S phase fraction and poor patient survival in b‐cell non‐Hodgkin's lymphoma , 2000, International journal of cancer.
[24] H. Saito,et al. Mutations of the p53 gene as a prognostic factor in aggressive B-cell lymphoma. , 1997, The New England journal of medicine.
[25] E. Campo,et al. p21WAF1/CIP1 AND MDM2 EXPRESSION IN NON‐HODGKIN'S LYMPHOMA AND THEIR RELATIONSHIP TO p53 STATUS: A p53+, MDM2−, p21− IMMUNOPHENOTYPE ASSOCIATED WITH MISSENSE p53 MUTATIONS , 1997, The Journal of pathology.
[26] E. White,et al. Bcl-2 blocks p53-dependent apoptosis , 1994, Molecular and cellular biology.
[27] A. Gerdes,et al. Disrupted p53 function as predictor of treatment failure and poor prognosis in B- and T-cell non-Hodgkin's lymphoma. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[28] R. Noelle,et al. Identification of Murine Germinal Center B Cell Subsets Defined by the Expression of Surface Isotypes and Differentiation Antigens1 , 2000, The Journal of Immunology.
[29] Elaine S. Jaffe,et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. , 1994, Blood.
[30] A. Levine,et al. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation , 1992, Cell.
[31] Jin-Hwang Liu,et al. p53 gene Mutations and rearrangements in non‐Hodgkin's lymphoma , 1999, Cancer.
[32] J. Child,et al. The Lymphoproliferative Disorders: Handbook of diagnosis, investigation and management , 1998, British Journal of Cancer.
[33] M. Piris,et al. p53 and bcl-2 expression in high-grade B-cell lymphomas: correlation with survival time. , 1994, British Journal of Cancer.
[34] J. Ellison,et al. Efficacy of fluorescence-based PCR-SSCP for detection of point mutations. , 1993, BioTechniques.
[35] R. Gascoyne,et al. Prognostic significance of Bax protein expression in diffuse aggressive non-Hodgkin's lymphoma. , 1997, Blood.
[36] K. Ohshima,et al. Prognostic clinicopathologic factors, including immunologic expression in diffuse large B‐cell lymphomas , 1999, Pathology international.
[37] Ash A. Alizadeh,et al. Ongoing immunoglobulin somatic mutation in germinal center B cell-like but not in activated B cell-like diffuse large cell lymphomas. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[38] S. Pileri,et al. A specific monoclonal antibody (PG-B6) detects expression of the BCL-6 protein in germinal center B cells. , 1995, The American journal of pathology.
[39] A. Levine,et al. The p53 proto-oncogene can act as a suppressor of transformation , 1989, Cell.
[40] W. Knapp,et al. Anatomical distribution of call antigen expressing cells in normal lymphatic tissue and in lymphomas. , 1982, Leukemia research.
[41] C. Benoist,et al. A powerful nonviral vector for in vivo gene transfer into the adult mammalian brain: polyethylenimine. , 1996, Human gene therapy.
[42] A. Harris,et al. Mutations in the p53 gene are not limited to classic 'hot spots' and are not predictive of p53 protein expression in high‐grade non‐Hodgkin's lymphoma , 1995, British journal of haematology.
[43] J Hermans,et al. CD44 expression predicts disease outcome in localized large B cell lymphoma , 1999, Leukemia.
[44] R. Maestro,et al. MDM2 overexpression does not account for stabilization of wild-type p53 protein in non-Hodgkin's lymphomas. , 1995, Blood.
[45] W. Wilson,et al. Relationship of p53, bcl-2, and tumor proliferation to clinical drug resistance in non-Hodgkin's lymphomas. , 1997, Blood.
[46] M. Gobbi,et al. How do patients with aggressive non-Hodgkin's lymphoma treated with third-generation regimens fare in the long-term? , 1999 .
[47] J. Blay,et al. The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the PARMA trial. Parma Group. , 1998, Blood.
[48] A. Sánchez-Aguilera,et al. Overall survival in aggressive B-cell lymphomas is dependent on the accumulation of alterations in p53, p16, and p27. , 2001, The American journal of pathology.
[49] J C Reed,et al. Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma. , 1997, Blood.
[50] P. Koduru,et al. Correlation between mutation in P53, p53 expression, cytogenetics, histologic type, and survival in patients with B-cell non-Hodgkin's lymphoma. , 1997, Blood.
[51] P. Gobbi,et al. Efficacy of two different ProMACE-CytaBOM derived regimens in advanced aggressive non-Hodgkin's lymphoma. Final report of a multicenter trial conducted by GISL. , 1998, Haematologica.
[52] J. Royds,et al. Elevated levels of MDM-2 and p53 expression are associated with high grade non-Hodgkin's lymphomas. , 1994, Cancer letters.
[53] Joe C. Adams,et al. Biotin amplification of biotin and horseradish peroxidase signals in histochemical stains. , 1992, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.
[54] David Beach,et al. p21 is a universal inhibitor of cyclin kinases , 1993, Nature.
[55] Emili Montserrat,et al. A predictive model for aggressive non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.
[56] J. Winter,et al. Two new monoclonal antibodies (LN-1, LN-2) reactive in B5 formalin-fixed, paraffin-embedded tissues with follicular center and mantle zone human B lymphocytes and derived tumors. , 1984, Journal of immunology.
[57] R. Tibshirani,et al. Molecular analysis of immunoglobulin genes in diffuse large B-cell lymphomas. , 2000, Blood.
[58] N. Berinstein,et al. Alterations of the p53 tumor suppressor gene in diffuse large cell lymphomas with translocations of the c-MYC and BCL-2 proto-oncogenes. , 1994, Blood.
[59] A. Levine,et al. Identification and characterization of multiple mdm-2 proteins and mdm-2-p53 protein complexes. , 1993, Oncogene.
[60] M. Oren,et al. Mdm2 promotes the rapid degradation of p53 , 1997, Nature.
[61] R. Schreiber,et al. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death , 1990, Nature.
[62] J. Benítez,et al. Correlation between mutations in p53 gene and protein expression in human lymphomas , 1997, American journal of hematology.
[63] K. Stefanaki,et al. Expression of p53, mdm2, p21/waf1 and bcl‐2 proteins in thymomas , 1997, Histopathology.
[64] D C Linch,et al. Prognostic significance of BCL-2 expression and bcl-2 major breakpoint region rearrangement in diffuse large cell non-Hodgkin's lymphoma: a British National Lymphoma Investigation Study. , 1996, Blood.
[65] J. Trent,et al. WAF1, a potential mediator of p53 tumor suppression , 1993, Cell.